Biomarker Core

该核心协调患者入组，组织临床数据，并收集临床标本和生物测定。在此过程中，核心研究将利用在斯坦福大学随访的肺动脉高压（PAH）、新生儿肺呼吸机诱导损伤（VIINL）或慢性肺病（CLD）风险患者和肺移植（LT）候选人的大型队列。他们将对细胞和液体进行最先进的生物测定，这将与反映疾病严重程度的生理终点有关。

This Core coordinates patient enrollment, organizes clinical data, and standardizes collection of clinical specimens and bioassays. In so doing, the Core will leverage the large cohorts of patients with Pulmonary Arterial Hypertension (PAH), at risk for Ventilator Induced Injury of the Newborn Lung (VIINL) or chronic lung disease (CLD) and candidates for Lung Transplantation (LT) followed at the Stanford. They will carry out an established platform of state-of-the-art bioassays for cells and fluids that will be related to physiological endpoints that reflect disease severity.